Every so often, a medical advance is so significant that it gives seasoned oncologists chills. This is currently the case for Revolution Medicines and their experimental therapy, daraxonrasib. In a recent late-stage study, the drug allowed patients with advanced disease to live twice as long as those receiving standard chemotherapy. For a field where progress is often measured in mere…